BCBSND district offices closed June 10-11

District offices in Bismarck, Grand Forks and Minot are closed June 10-11 for staff training. We will reopen June 12. For help, contact us.

Show More

Long-Acting Insulin Prior Authorization Program Update

Impacting Commercial Lines of Business

Effective Aug. 1, 2025, Blue Cross Blue Shield of North Dakota (BCBSND) has updated the Long-Acting Insulin Prior Authorization (PA) Program to include additional agents: Toujeo, Basaglar and Insulin glargine 300 units/ml. 

The complete list of program target agents is shown below.

Preferred Agent(s)

  • Glargin-yfgn (insulin glargine-yfgn)
  • Semglee (insulin glargine-yfgn)
  • Toujeo (insulin glargine)

Non-Preferred Target Agent(s)

  • Insulin glargine
  • Lantus (insulin glargine)
  • Rezvoglar (insulin glargine-aglr)
  • Basaglar (insulin glargine)
  • Insulin glargine 300 units/ml

To view this PA program summary, visit Long Acting Insulin Prior Authorization with Quantity Limit Program Summary.

Questions?
Contact our Provider Service Center at 800-368-2312.